| Title | Narrative review: statin-related myopathy. | | Author(s) | Joy TR, Hegele RA | | Institution | Robarts Research Institute and Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada. joan_warren@nih.gov | | Source | Ann Intern Med 2009 Jun 16; 150(12):858-68. | | MeSH | Diagnosis, Differential
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscular Diseases
Risk Factors
| | Abstract | Statin-related myopathy is a clinically important cause of statin intolerance and discontinuation. The spectrum of statin-related myopathy ranges from common but clinically benign myalgia to rare but life-threatening rhabdomyolysis. Observational studies suggest that myalgia can occur in up to 10% of persons prescribed statins, whereas rhabdomyolysis continues to be rare. The mechanisms of statin-related myopathy are unclear. Options for managing statin myopathy include statin switching, particularly to fluvastatin or low-dose rosuvastatin; nondaily dosing regimens; nonstatin alternatives, such as ezetimibe and bile acid-binding resins; and coenzyme Q10 supplementation. Few of these strategies have high-quality evidence supporting them. Because statin-related myopathy will probably become more common with greater numbers of persons starting high-dose statin therapy and the increasing stringency of low-density lipoprotein cholesterol level targets, research to better identify patients at risk for statin myopathy and to evaluate management strategies for statin-related myopathy is warranted. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
Review
| | PubMed ID | 19528564 |
|
